Research on non-small cell lung cancer (A549 and SW-1573 cells) demonstrated that synthetic cannabinoid agents, including CB1/CB2 agonists WIN 55,212–2 and JWH-015, significantly decreased the focal adhesion complex crucial for cancer cell migration. This evidence concerns the gene CNR2 and non-small cell lung carcinoma.